Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis.
暂无分享,去创建一个
W. Liang | Jianxing He | Wei Wang | G. Peng | Jianfei Shen | Jiaxi He | Z. Guo | Yaxiong Zhang | Gang Chen | Long Jiang | Minghan Jia | Jianxing He | Shiyang Kang | Weijia Feng
[1] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] S. Soefje,et al. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[3] S. Gettinger,et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. , 2014 .
[4] S. Gettinger,et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). , 2014 .
[5] S. Gettinger,et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. , 2014 .
[6] M. Dolled-Filhart,et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). , 2014 .
[7] M. Dolled-Filhart,et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). , 2014 .
[8] S. Gettinger,et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. , 2014 .
[9] N. Rizvi,et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. , 2014 .
[10] A. Rossi,et al. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? , 2013, Cancer treatment reviews.
[11] C. Drake,et al. Molecular Pathways Molecular Pathways : Coexpression of Immune Checkpoint Molecules : Signaling Pathways and Implications for Cancer Immunotherapy , 2013 .
[12] L. Sequist,et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). , 2013 .
[13] S. Gettinger,et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). , 2013 .
[14] R. Herbst,et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). , 2013 .
[15] Tanja Cufer,et al. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. , 2013, European Journal of Cancer.
[16] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[17] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[18] L. Sequist,et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). , 2012 .
[19] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[20] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[21] J Zhang,et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer , 2011, Medical oncology.
[22] Jae Jin Lee,et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). , 2010, Lung cancer.
[23] U. Jian-zhong. Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer , 2010 .
[24] Liu Xiao-qing. Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer , 2010 .
[25] P. Zatloukal,et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Gregory J Riely,et al. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.
[27] Robert Pirker,et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.
[28] G. Gores,et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.
[29] R. Ramlau,et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Yang Jun-quan. RRM1 Expression and Efficacy Analysis of Gemcitabine in Advanced Non-small Cell Lung Cancer , 2009 .
[31] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.
[32] D. Mavroudis,et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine , 2008, British Journal of Cancer.
[33] J. Allison,et al. Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.
[34] G. Bepler,et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Bauke Ylstra,et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.
[36] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[37] G. Bepler,et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.
[38] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[39] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.